Covid-19: Perspectives on Innate Immune Evasion

Nima Taefehshokr¹, Sina Taefehshokr², Nima Hemmat² and Bryan Heit¹,³*

¹ Department of Microbiology and Immunology, Center for Human Immunology, The University of Western Ontario, London, ON, Canada, ² Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, ³ Robarts Research Institute, London, ON, Canada

The ongoing outbreak of Coronavirus disease 2019 infection achieved pandemic status on March 11, 2020. As of September 8, 2020 it has caused over 890,000 mortalities world-wide. Coronavirus infections are enabled by potent immuno-evasive mechanisms that target multiple aspects of innate immunity, with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) able to induce a cytokine storm, impair interferon responses, and suppress antigen presentation on both MHC class I and class II. Understanding the immune responses to SARS-CoV-2 and its immune evasion approaches will improve our understanding of pathogenesis, virus clearance, and contribute toward vaccine and immunotherapeutic design and evaluation. This review discusses the known host innate immune response and immune evasion mechanisms driving SARS-CoV-2 infection and pathophysiology.

Keywords: SARS-CoV-2, macrophage, innate immune, MHC trafficking, cytokine - immunological terms

INTRODUCTION

In December 2019, the outbreak of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of Coronavirus disease 2019 (COVID-19) – began in Wuhan, Hubei Province, China, from where it spread rapidly. On March 11, 2020 the World Health Organization declared COVID-19 a global pandemic (1, 2). COVID-19 is not the first severe respiratory disease outbreak caused by coronaviruses (CoVs) in humans, with two epidemic diseases – severe acute respiratory syndrome (SARS-CoV) in 2003–2004 and Middle East respiratory syndrome (MERS-CoV) in 2012 – caused by similar zoonotic transmission of CoVs (3). The primary symptoms of COVID-19 are similar to those of SARS-CoV and MERS-CoV: fever, fatigue, dry cough, discomfort in the upper chest, occasional diarrhea, and dyspnea. Severe cases exhibit secondary infections, cytokine-storm driven sepsis, and multi-organ failure (4, 5). COVID-19 patients primarily develop pneumonia, lymphopenia, and feature pulmonary ground glass opacity on chest CT (6, 7).

Coronaviruses are in the Coronaviridae family, enveloped viruses with a positive-sense single-stranded RNA genome ranging from 26 to 32 kb in size (8). In humans CoV infections are common, with four CoVs (229E, NL63, OC43, and HKU1) causing ~10% of common cold cases (4). The infection of human cells by CoVs is mediated by interactions between envelope-anchored spike glycoprotein (S-protein) of CoV with one of two host cell receptors: angiotensin-converting enzyme 2 (ACE2) or CD147 (9, 10). The S-protein consists of two subunits: S1 which functions as the receptor-binding domain (RBD), and S2 which drives the fusion of the viral membrane with the host cell membrane (11). Spike glycoprotein activation and viral entry is mediated by cleavage of the S protein by the host transmembrane protease, serine 2 (TMPRSS2) (12, 13). Sequencing of SARS-CoV-2 from patients revealed that it shares 79.6% homology to SARS-CoV, 50% MERS-CoV, and
The RBD of SARS-CoV-2 is derived from a pangolin-infecting CoV and exhibits a 10-fold increase in affinity between the RBD and ACE2 compared to SARS-CoV, further consistent with ACE2 as the prominent receptor for SARS-CoV-2 (15). This increase in receptor affinity was generated by the recombinant of the pangolin CoV and a bat SARS-like CoV within the RBD region, a characteristic which could lead to a more efficient cell entry (16). Interestingly, crystal structure evaluation by cryo-electron microscopy (Cryo-EM) showed that SARS-CoV-2 RBD is biased toward the lying state conformation, which reduces receptor binding by burying the RBD within the spike protein trimer. In contrast, the SARS-CoV RBD is mostly in the exposed “standing up” state which favors receptor binding (17-19). This bias toward the lying state may favor SARS-CoV-2 immune evasion by masking the RBD domain from neutralizing antibodies. There have been reports that SARS-CoV-2 can also gain entry into cells via CD147, but the importance of this pathway for viral entry, and the concordant receptor-binding motifs, remain largely unelucidated (10).

Less well understood than SARS-CoV-2’s biology is its resulting immune responses, immunopathology, and immune evasion mechanisms. Understanding these responses will be vital for the development of immunotherapies or vaccines against COVID-19 (1, 20). Coronavirus are adept at manipulating immune responses and interfere with the interferon (IFN) pathway, with several structural proteins (M and N) and non-structural protein (NSP1 and NSP3) from SARS-CoV and MERS-CoV acting as interferon antagonists (21). These CoVs also interfere with pattern recognition receptor (PRR) signaling such as Toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I) like receptors (22), and generate a strong inflammatory response (23, 24). This drives a non-productive inflammation, resulting in a cytokine storm and disseminated damage to the host, while avoiding induction of an anti-viral interferon response. Indeed, an early study of 41 COVID-19 patients identified increased levels of pro-inflammatory cytokines including IL-2 and IL-7, with more severe disease producing elevated G-CSF, MCP-1, MIP-1α, IP-10, and TNF-α (25). These pro-inflammatory cytokines drive an influx of neutrophils and other myeloid cells into the lung, producing a strong local inflammatory response and significant immunopathology (26). This is consistent with SARS and MERS, indicating that a cytokine storm and lymphopenia play a crucial role in the COVID-19 pathogenesis (25, 27, 28). In addition to manipulating cytokines, CoVs also manipulate other immunological processes including antigen presentation (29). In this review we discuss the major innate immunological pathways involved in responses to CoV infection, and the mechanisms used by SARS-CoV-2 and related CoVs to overcome these defenses.

**INTERFERONS AND CYTOKINES**

The innate immune system is an evolutionary conserved set of cellular and chemical defenses critical for the recognition and restriction of pathogens, and for the subsequent activation of an adaptive immune response (21). Innate immunity is initiated by pathogen-associated molecular patterns, evolutionarily conserved molecular structures specific to pathogens that act as ligands for PRRs. Ligand binding triggers signaling pathways that coverage on transcription factors including NF-κB, IRF3, and AP-1, which synergistically promote type I interferon (IFN-I) production. These cytokines act in a paracrine fashion on neighboring cells via the IFN-α/β receptor (IFNAR) and induce expression of interferon-stimulated genes (ISGs) (30). Interferon-stimulated genes are an essential component of innate antiviral defense, acting to both limit viral entry and restricting viral replication after a virus enters a host cell (31, 32). Interferon-stimulated gene expression is driven predominantly by IFNAR-mediated activation of the Jak/STAT pathway, resulting in binding of STAT1 homodimers and STAT1/2 heterodimers to the promoter region of ISGs.

Severe acute respiratory syndrome coronavirus 2 has evolved multiple mechanisms to manipulate this key antiviral response. It was recently demonstrated that ACE2 is an ISG, suggesting that SARS-CoV-2 may exploit IFN-driven ACE2 upregulation to enhance infection (31). Furthermore, CoVs including SARS-CoV and MERS-CoV encode multiple proteins which antagonize IFN signaling. These functions represent a key anti-immune mechanism of SARS-like CoVs, and are critical for the viral manipulation of the innate immune response and promoting early viral pathogenesis (33, 34). Because SARS-CoV-2 may utilize ISGs to enhance infectivity, and because it is unclear whether the IFN response restricts SARS-CoV-2 replication, it is unknown if IFN-directed therapies will be beneficial to COVID-19 patients. A recent study found that COVID-19 patients who failed to produce IFN-α experienced more severe clinical outcomes (35). In addition, IFN-α potently inhibits the replication of SARS-CoV-2 in vitro (36). The National Health Commission of China has proposed guidelines for the treatment of SARS-CoV-2, which includes aerosolized recombinant IFN-α, based on the observation that IFN-α inhibits SARS-CoV replication in vitro (37, 38). At the time of this writing only one retrospective analysis of these treatment guidelines has been published, identifying a modest benefit of IFN-α in combination with lopinavir, ritonavir, and ribavirin (39). The combinatorial use of these drugs makes it difficult to assess the role of IFN-α alone, but these data suggest that induction of the IFN-I pathway produces a beneficial response in SARS-CoV-2 patients. In addition to IFN-I, type III IFNs (IFN-λ) exhibit more potent antiviral functions than IFN-α in treating influenza infection, without activating inflammation and tissue damage induced by IFN-α (40, 41). On the other hand, it has been shown that IFN-λ treatment could inhibit bacterial uptake by neutrophils in the lung during influenza superinfection, suggesting that IFN-λ may increase susceptibility to lower respiratory tract infection, potentially increasing the risk of super-infection of COVID-19 patients to super-infection with other pathogens (42, 43). Similar to type I IFNs, IFNs-λ is decreased during COVID-19 infection (44), and IFN-λ hinders SARS-CoV-2 replication in vitro in human intestinal epithelial cells (45). Interestingly, IFN-λ is present in lower airways in COVID-19 patients where it mediates antiproliferative effects in during the repair of the lung epithelium. This antiproliferative effect occurs via...
p53 induction, but due to its slowing of epithelial repair, may increase the risk of life-threatening bacterial superinfections in the lung during both influenza and COVID-19 infection (46, 47). Thus, timing and duration are critical parameters of IFN action and in COVID-19 patients who contract a secondary bacterial infection, it might be crucial to intervene with recombinant interferons when virus is in upper airways. Later in disease, when inflammation is increased in the lower airways, it may be beneficial to block signaling cascades initiated by interferons and other inflammatory cytokines in order to control superinfecting pathogens.

The mechanisms used by CoVs to manipulate the IFN response can be divided into three categories: (1) avoidance, where the virus protects itself from recognition by PRRs, (2) IFN induction suppression, where the virus inhibits the transcription of interferons (48), and (3) IFN signaling suppression, where viral proteins inhibit IFNAR signaling (49). The viral membrane (M) protein, nucleocapsid (N) protein, and the non-structural proteins NSP1, NSP3b, NSP4a, NSP4b, NSP15, play crucial roles in modulation of the host immune response (50). The SARS-CoV N protein modulates signaling though the TGF-β receptor by forming a complex with Smad3. This enhances Smad3/p300 transcription, driving lung fibrosis. This interaction also prevents Smad3 from complexing with Smad4, thereby enhancing the survival of infected cells by antagonizing TGF-β-sensitized apoptosis (51). Moreover, SARS-CoV and MERS-CoV hide their RNA genome from host detection by cytosolic (e.g., RIG-I) and endosomal (e.g., TLR3/7) PRRs by replicating in double membrane vesicles that excludes these PRRs (52, 53). Indeed, both the induction of IFN-α or β and the ability to restrict both MERS-CoV and SARS-CoV infection requires TLR3 signaling, and SARS-CoV is able to antagonize the TLR signaling pathway via its papain-like protease (PLpro) (54, 55). Finally, during viral replication the SARS-CoV and MERS-CoV N protein catalytically modifies host proteins through SUMOylation and ubiquitination, via interactions with the host proteins hUbc9 and TRIM25, respectively (22, 56). While the targets of N protein-mediated SUMOylation remains unclear, N protein-targeted ubiquitination targets RIG-I for proteasomal degradation, thus depleting the cell of a critical virus-detecting PRR (22). The N proteins of SARS-CoV and SARS-CoV-2 are 90% conserved, suggesting that these immune avoidance activities are likely conserved in SARS-CoV-2 (Supplementary Figure 1). Thus, through manipulating multiple components of the host’s PRR system, CoVs are able to limit or avoid activation of many host anti-viral processes.

Analysis of MERS-CoV patients with differing severity has demonstrated significantly lower IFN-1 responses in patients who succumb to infection versus to those who recover, highlighting the importance of IFN induction (57). It has been shown that the IFN pathway is inhibited by SARS-CoV-2 to an extent similar to the inhibition by MERS-CoV and SARS-CoV, thereby impairing both innate T cell antiviral responses (58–60). While the specific molecular pathways mediating the suppression of IFN induction in SARS-CoV-2 have not been fully elucidated, these mechanisms are well understood in SARS-CoV and MERS and are likely conserved (Figure 1). Severe acute respiratory syndrome coronavirus NSP1 promotes the degradation of IFN-β mRNA (61), while ORF6 disrupts IFN induction by preventing the transport of IRF3 and STAT1 into the nucleus (62, 63). This occurs via two mechanisms, with ORF6 and ORF3b reducing IFNAR signaling by disrupting STAT1 nuclear import and promoting STAT1 proteolytic degradation, respectively (62, 64). ORF4a interacts with dsRNA and the RIG-I like receptor cofactor PACT, inhibiting IFN induction (65, 66). ORF4b blocks IFN induction by binding to both TBK1 and IKKe (67, 68). MERS-CoV’s ORF4b, 5, and M proteins have been shown to prevent nuclear translocation of IRF3 (69). At least some of these pathways are conserved in SARS-CoV-2, with a recent study demonstrating that SARS-CoV-2 ORF3b is a potent IFN antagonist, which suppresses IFN induction more efficiently than the SARS-CoV ortholog (70). Notably, a recent study reported that ORF3b is one of the most common antibody-recognized antigens during early stage COVID-19 infection (71), suggesting that ORF3b is highly expressed in the acute stage of the infection and may represent an immunodominant epitope. NSP13, NSP14, NSP15, and ORF6 have been suggested to function as IFN antagonists by suppressing IFN signaling (72). Additionally, SARS-CoV-2 M protein through interacting with RIG-I/MDA-5-MAVS signaling pathway inhibits the production of type I and III IFNs (73). As discussed above, the SARS and MERS PLpro is a deubiquitinating/deISGylating enzyme (74), which enhances immunoevasion by downregulating IFN-β transcription (75). The PLpro proteins of SARS-CoV and SARS-CoV-2 are 76% conserved, suggesting that this activity is likely conserved in SARS-CoV-2 (Supplementary Figure 2).

COVID-19 patients experience a cytokine storm that drives much of the pathophysiology of the disease. Both pro-and anti-inflammatory circulating cytokines increase in SARS-CoV-2 patients, with cytokines including G-CSF, TNFα, MCP1, IL-10, IL-2 and IL-7 becoming elevated in critically ill patients (76, 77). IL-6 is thought to be a major driver of pathology, with the highest levels observed in non-survivors and critically ill COVID-19 patients (78, 79). The mechanism leading to elevated IL-6 in severe COVID-19 is not currently clear, but is likely driven through activation of virus-specific PRRs. However, other pathways are likely involved in patients with severe disease. For example, SARS-CoV triggers the production of oxidized phospholipids, which then drives IL-6 production via TLR4 (80). The upregulation of IL-6 is an established effect of TLR4 signaling, which occurs via NF-κB and MAPK signaling pathways (81). Finally, the N protein of SARS-CoV-2 induces the expression of IL-6 in infected airway epithelium by binding to the NF-κB regulatory elements of the IL-6 promoter (82). Clearly, SARS-CoV-2 pathology is driven by an unbalanced cytokine response, although the viral processes driving these responses remain to be fully elucidated.

**PATTERN RECOGNITION RECEPTOR EVASION**

In addition to modulating IFN-1 and IL-6 responses, CoVs also engage in immune evasion through limiting PRR activation.
FIGURE 1 | CoV Innate Immune Evasion. The innate immune response to CoVs is activated upon detection of viral pathogen-associated molecular patterns, such as double-stranded RNA, via host PRRs such as RIG-I. Following viral recognition, transcription factors including NF-κB, AP-1 and IRF3 are activated and translocate to the nucleus where they induce the expression of interferons. Both MERS-CoV and SARS-CoV, through their M, N, non-structural proteins (NSP1, 3b, 4a, 4b, 5, 6), and PLpro, have developed mechanisms to interfere with these signaling pathways. This alters the cytokine secretion profile of infected cells to enhance the recruitment of myeloid immune cells over NK cells, which in turn produce more cytokines, creating a cycle of inflammation that damages the lung. Many of these processes are likely conserved in SARS-CoV-2.

Coronaviruses replicate in a double-membrane structure derived from the endoplasmic reticulum (52). The endoplasmic reticulum lacks PRRs, and as such, this compartment secludes the replicating virus from both cytosolic PRRs such as RIG-I and from endosomal PRRs such as TLR3 and TLR7 (83ñ85). In addition to physically excluding PRRs from the site of viral replication, CoVs suppress PRR signaling directly. As discussed above, coronaviral N-proteins direct the host cell ubiquitination machinery to target the cytosolic RNA sensor RIG-I, leading to RIG-I degradation (22). Coronaviruses also suppress TLR signaling; for example, the MERS-CoV spike protein induces expression of the negative TLR regulator IRAK-M in macrophages through activating the dipeptidyl-peptidase 4 receptor (86). Likewise, SARS-CoV induces the broad dysregulation of TLR-associated signaling molecules in infected macrophages, although the specific mechanism of this dysregulation and its net effect on TLR signaling has not been established (87). While these activities have not yet been reported in SARS-CoV-2, the high degree of conservation between it, MERS-CoV, and SARS-CoV indicates that some manipulation of the PRR system likely occurs during SARS-CoV-2 infection.

NEUTROPHILS
Neutrophilia is an early indicator of SARS-CoV-2 infection, although it is unclear whether this increase is due to the release of the marginated neutrophil pool versus the release of bone marrow-derived cells (88ñ90). While the extent to which neutrophils are responsible for COVID-19 pathophysiology is unclear, significant neutrophil infiltration has been reported in autopsied COVID-19 patients (91, 92). Infiltration is not the only mechanism by which neutrophils may cause pathology on COVID-19 patients. Indeed, pathological effects of neutrophil extracellular traps (NETs) have been identified in a variety of inflammatory conditions including thrombosis, sepsis, and respiratory failure (93ñ95). Neutrophil extracellular traps are comprised of extracellular DNA fibers, histones,
microbicidal proteins, proteases such as neutrophil elastase, and oxidant enzymes such as myeloperoxidase, that are released by neutrophils in response to many infectious agents. If not regulated properly, NETs initiate and propagate inflammation and thrombosis (96–98).

For the first time, a recent study showed that NETs released by neutrophils contribute to organ damage and mortality in COVID-19 patients (99). This is consistent with another recent study that identified markers of NET release, including myeloperoxidase-DNA and citrullinated histone H3, in COVID-19 patients, with the sera of these patients potently inducing NETosis of control neutrophils in vitro (100). The high levels of IL-6 observed in COVID-19 patients is likely a driver of this NETosis, as in other inflammatory diseases IL-6 induces the systemic release of NETs (101, 102). Additional triggers of NETosis include virus-damaged epithelial cells (103, 104), activated endothelial cells (105), activated platelets (106, 107), and inflammatory cytokines such as IL-1β (108, 109). Transcriptional analysis of bronchoalveolar lavage fluid and peripheral blood mononuclear cells from COVID-19 patients showed that elevated levels of CXCL2 and CXCL8 contributes to the recruitment of neutrophils to the lung, aggravating the inflammatory response (110). Moreover, activated neutrophils express peroxin, factor B, and C3, thus driving complement activation (111), a marker of severe COVID-19 disease (112, 113). Consistent with a role for NETs in COVID-19 immunopathology, a small clinical trial demonstrated a protective effect of dipyridamole, an FDA approved drug which inhibits NETosis via blocking signaling through adenosine A2A receptors (93, 114).

**NK CELLS**

Natural killer (NK) cells are essential to the control of viral infections, and functional impairment of NK cells correlate with persistence of SARS-CoV-2 (115, 116). Reduced peripheral blood NK cell numbers is frequently observed in severe COVID-19 patients (89, 116–118). Killer-immunoglobulin like receptors (KIRs) which are expressed on plasma membrane of NK cells alongside CD16 play crucial roles in NK cells licensing and their subsequent cytotoxic functions (119). In peripheral blood, NK cells expressing KIRs and CD16 are significantly decreased in SARS-CoV and SARS-CoV-2 infection, suggesting either impaired maturation of NK cells or migration of circulating NK cells into the peripheral tissues of SARS-CoV-2 patients (120, 121). Moreover, lower NK cell numbers correlate with higher IL-6 plasma concentrations in SARS-CoV-2 infection (117, 120). In vitro, IL-6 and soluble IL-6 receptor impair perforin and granzyme B production by healthy donor NK cells, which could be restored by treatment with the IL-6R inhibitor tocilizumab (122). Furthermore, secretion of cytokines such as IL-12 by macrophages and dendritic cells (DCs) could promote NK cell proliferation, cytotoxicity, survival, and IFN-γ production (123, 124). The later may occur through IFN-λ-mediated IL-12 production by macrophages (125), suggesting that early IFN-γ production and NK cell stimulation may act to limit SARS-CoV-2 infection.

The expression of inhibitory receptor NKG2A on NK cells results in the functional exhaustion of NK cells in chronic viral infection and cancer (126, 127). It is reported that NK cells become functionally exhausted in SARS-CoV-2 patients, as evidenced by increased NKG2A expression and decreased expression of CD107a, IFN-γ, IL-2 and granzyme B in NK cells (76, 116). Additionally, recent studies reported upregulated expression of the genes encoding inhibitory receptors including TIM3 and LAG3 in NK cells from COVID-19 patients (60, 128). The implications of this high incidence of exhausted NK cells in SARS-CoV-2 patients remain elucidated. While NK cell numbers and activity appear to be diminished in COVID-19 patients, anti-S protein antibodies are capable of inducing NK-cell mediated antibody-dependent cell cytotoxicity in an in vitro model of SARS-CoV-2 infection, indicating that normally functional NK cells should contribute to protective immunity against SARS-CoV-2 (129).

**MACROPHAGES**

Macrophages are one of the primary drivers of innate immunity in response to CoV infection, with macrophage activity driving both inflammation, and much of the pathology, in COVID-19 patients (130). Macrophages in the lung and upper respiratory tract act as sentinel cells and are among the first immune cells to encounter incoming virions. In response, these macrophages can limit early viral replication through initiating a IFN-γ response, as well as through initiating an inflammatory response to recruit additional immune cells (131). While this inflammatory response is required to initiate immune responses against SARS-CoV-2, excess inflammation in the form of a cytokine storm contributes to the mortality associated with COVID-19 (132). The lung has at least two distinct macrophage populations - interstitial macrophages and alveolar macrophages (AMs) (125), and there are at least two subsets of interstitial macrophages – of which, the nerve-and airway-associated macrophages (NAMs) may be particularly important for restricting inflammation in response to CoV's. Nerve-and airway-associated macrophages are highly divergent from AMs in their gene expression profile and tissue localization. Nerve-and airway-associated macrophages are located in the lung interstitia, closely associated with innervating nervous tissue, and have a different ontology and growth factor dependence than AMs (133). During influenza infection NAMs are critical in limiting viral-induced inflammation, whereas AMs are pro-inflammatory and required for viral clearance. These findings indicate that AMs are anti-viral and pro-inflammatory, whereas NAMs are and act to prevent excessive and damaging inflammation. Importantly, during influenza NAMs suppress IL-6 production, indicating that NAMs may be a critical control point in determining IL-6 levels, and thus may regulate the cytokine storm in COVID-19 patients (133).

Consistent with these observations, distinct macrophage populations were identified in the lungs of COVID-19 patients, and while this study did not investigate NAMs, it did identify enrichment of anti-inflammatory monocyte-derived (FCN1high)
Macrophages in patients with mild disease, while resident pro-fibrotic (SPP1\textsuperscript{high}) and inflammatory AM (FAPB4\textsuperscript{+}) populations dominated in patients with severe COVID-19 (134). Combined, these studies demonstrate that macrophage polarization and the relative proportion of macrophage subtypes is a major factor in COVID-19 severity.

Macrophages can be infected by SARS-CoV-2 (130), indicating that SARS-CoV-2 directly manipulates macrophages to evade immunity. It is unclear what effect SARS-CoV-2 infection has on macrophage function, but infection of macrophages by other CoVs is known to induce altered functional states. Macrophages infected by MERS-CoV express high levels of major histocompatibility complex I (MHC I), CD80 and CD86, but lack major histocompatibility complex II (MHC II), indicating that MHC II presentation is impaired by MERS-CoV (58, 135). Consistently, MHC II downregulation was recently demonstrated in monocytes and B cells from COVID-19 patients (128). Moreover, monocyte HLA-DR is downregulated in severe COVID-19 patients, with expression partially restored by an IL-6 inhibitor (136). The mechanism of MHC II downregulation is not completely understood, but is due in-part to changes in the epigenetic landscape of the infected cells (137). Indeed, the epigenetic downregulation of MHC II is a mechanism shared by other CoVs, for example, the human CoV-EMC also downregulates MHC II via epigenetic reprogramming (29). However, epigenetic reprogramming of antigen presentation is not universal, and for example, is not a feature of SARS-CoV despite this virus also limiting antigen presentation on MHC II (29).

The recently published interactome of SARS-CoV-2 provides some potential insights into mechanisms by which this virus may interfere with macrophage function (138). The blockade of interferon signaling, described above, would limit ISG expression in macrophages, including cytokine-induced MHC II expression (139). The SARS-CoV-2 protein Nsp5 interacts with the epigenetic regulator histone deacetylase 2 (HDAC2), which regulates MHC II expression and cytokine production (138, 140, 141). While it is unknown whether SARS-CoV-2 inhibits or enhances HDAC2 activity, this interaction indicates a potential direct modulation of the cytokine storm and antigen presentation. Nsp13 and ORF8 of SARS-CoV-2 interacts with multiple components of the Golgi trafficking system and may utilize this as a mechanism to restrict MHC export to the cell surface. Indeed, a recent study demonstrated that ORF8 of SARS-CoV-2 can directly bind to MHC I molecules at endoplasmic reticulum and redirect them to autolysosomes for degradation (142). This is a common approach used by viruses to limit antigen presentation; for example, the HIV Nef protein restricts antigen presentation on MHC I by redirecting MHC trafficking toward the Golgi (143, 144). Lastly, SARS-CoV-2’s Nsp10 interacts with the endocytosis regulator AP2, a critical regulator of MHC II trafficking to antigen loading compartments (138, 145, 146). While these immune evasionary mechanisms remain largely theoretical, the ability of SARS-CoV-2 to infect macrophages and interact with proteins central to macrophage function suggests a potent ability to modulate macrophage activity, and through this, the systemic immune response.

**DENDRITIC CELLS**

Dendritic cells are key players in antigen presentation, cytokine production, priming specific T cell responses, and a loss of DCs function could lead to delayed immune responses in COVID-19 patients (147). Previous studies demonstrated that SARS-CoV infects DCs, resulting in poor antiviral cytokine expression with an upregulation of inflammatory chemokines including MIP-1\textalpha (148). SARS-CoV also enhanced pro-inflammatory cytokine (IL-6 and IL-12) production by DCs in response to secondary activation signals by bacterial LPS, further contributing to a damaging inflammatory response (149). Moreover, plasmacytoid dendritic cells (pDCs) have been identified as a subset of DCs able to secrete large amounts of IFN I after contact with CoVs (150), although this is not universal – MERS-CoV infection induces significantly higher type I and III IFNs production by pDCs than does SARS-CoV (151). While the role of DCs in COVID-19 remains largely unexplored, the high levels of IFN-I\textalpha produced by these cells suggests a protective role.

Severe acute respiratory syndrome coronavirus 2 infection appears to target DCs directly – a recent study identified reduces DC frequency and functionally in COVID-19 patients, and a concordant impairment in the subsequent activation of T cells. Thus, in addition to further driving the cytokine storm, SARS-CoV-2 may infect DCs to limit DC maturation, and thus suppress T cell-mediated responses (44, 152, 153). This may represent a critical juncture in disease progression, as interference of T cell activation by modulating DC maturation could account for the lack of long-lasting humoral immunity and other defects in adaptive immunity associated with CoV infection. While infection of DCs appears to play an important role in driving the cytokine storm and modulating T cell responsiveness to SARS-CoV-2, the specific mechanisms used by the virus to alter DC function remains to be investigated.

**TRAINED IMMUNITY: A DEFENSE AGAINST COVID-19?**

Recent studies have shown that innate immune populations may possess a memory phenotype, termed Trained Immunity (TRIM), wherein innate immune cells undergo mitochondrial, metabolic, and epigenetic reprogramming following exposure to a pathogen (154), making the cell more responsive to subsequent pathogen exposures. Unlike with adaptive immunity, this “training” primes the cell to respond in an enhanced manner not only to the initial pathogen, but also to other pathogens encountered during the multi-week period over which TRIM lasts (154). TRIM can be effective against viral pathogens – for example, aerosolized bacterial lysates enhanced innate immune responses and increase survival against influenza A and other respiratory viruses (155, 156).

The induction of TRIM by Bacillus Calmette-Guerin (BCG) and other vaccines has been extensively demonstrated (157, 158). A recent study demonstrated that BCG administration to low-weight newborns reduced mortalities from infectious diseases by 43% over the neonatal period (159). It is tempting to
postulate that the decreased incidence and rate of complications of COVID-19 reported in children (160) may be partially attributed to the frequent vaccinations – and therefore the frequent induction of TRIM – that occurs during routine childhood vaccination schedules. Encouraging studies have shown a correlation between universal BCG and influenza vaccination policies and reduced mortality rates in COVID-19 infection (161, 162), and while these studies are not directly indicative of a causal relationship between these vaccinations and protection against SARS-CoV-2, they suggest that using existing approved vaccines to induce TRIM may be a viable approach to limit the negative effects of COVID-19 (157, 158). Consequentially, a number of studies are investigating whether BCG and MMR vaccines can attenuate COVID-19 pathology (163–166). While existing vaccines represent the quickest avenue to leverage TRIM as a preventative measure for COVID-19, other compounds may provide superior protection. For example, β-glucan polysaccharides found in the cell wall of bacteria, yeast and fungi, are known potent initiators of TRIM (167). β-glucans exert antiviral effects and decrease the severity of several respiratory viruses (168, 169). Orally administered β-glucans traffics into lymph nodes and spleen, where they activate DCs, leading to the expansion and activation of antigen-specific T cells and enhance T cell production of effector cytokines such as IFN-γ (170). This enhanced T cell activity results from β-glucan induced IFN-β production by DCs, which enhances the production of IFN-γ and Granzyme-B by CD8+ T cells (171). While β-glucans are commonly consumed by humans in foods prepared with yeast, care needs to be taken when considering their use for inducing TRIM in SARS-CoV-2 patients, as some studies have shown that β-glucans enhance M1 polarization of AMs – a phenomenon that may enhance the cytokine storm induced by SARS-CoV-2 (172, 173).

FUTURE PROSPECTS AND CONCLUSION

The rapid spread of SARS-CoV-2 has become a global concern. Currently, there are no approved drugs or vaccines to treat human CoVs, but recent advances in our understanding of the immune response and immune evasion mechanisms of CoV’s opens up many therapeutic avenues. These include mechanisms for limiting viral entry and replication, promoting viral clearance, and inducing productive anti-CoV immune responses. Investigating how SARS-CoV-2 modifies gene expression in innate immune cells will be crucial to identifying immune mechanisms that could be modulated to improve patient outcomes. Addressing IFN evasion mechanisms and preventing viral immune evasion may contribute to enhancing viral clearance and lessening immunopathology. While a major driver of the cytokine storm in COVID-19 patients, IL-6 has both pro- and anti-inflammatory properties, giving it a complex role in COVID-19 pathology. Inhibition of IL-6 signaling and elucidation of the mechanism which elevates IL-6 in patients will help to find new potential strategies to reduce pathology during COVID-19 infection. Finally, newly available tools such as next generation sequencing will provide key information on the clinical features of the disease and potential targets for the development of drugs and vaccines. While an effective treatment for COVID-19 remains elusive, this large array of tools and knowledge should enable the rapid development of preventative and therapeutic treatments for this newly emerged disease.

AUTHOR CONTRIBUTIONS

NT prepared the main body of the manuscript, with assistance from ST. NH performed the bioinformatics analysis. BH supervised the project and assisted in the authoring and revision of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

The work in BH’s laboratory was funded by the Canadian Institute for Health Research Operating Grant (Project Grant 406738) and Ontario Ministry of Research and Innovation Early Researcher Award.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.580641/full#supplementary-material

REFERENCES

1. Prompetchara E, Ketlow C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. (2020) 38:1–9.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33.
3. De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. (2016) 14:523–34. doi: 10.1038/nrmicro.2016.81
4. Paules CI, ston HD, Fauci AS. Coronavirus Infections—more than just the common cold. JAMA. (2020) 323:707–8. doi: 10.1001/jama.2020.0757
5. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. (2020) 395:e52. doi: 10.1016/s0140-6736(20)30558-4
6. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. (2020) 395:514–23. doi: 10.1016/s0140-6736(20)30154-9
7. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. (2020) 579:265–9.
8. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, recombination, and pathogenesis of coronaviruses. Trends Microbiol. (2016) 24:490–502. doi: 10.1016/j.tim.2016.03.003
28. Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, et al. Clinical features of COVID-19: current state of the science. *J Allergy Clin Immunol* (2019) 143:506–10. doi: 10.1016/j.jaci.2019.03.012

29. Josset L, Menachery VD, Gralinski LE, Agnihothram S, Sova P, Carter VS, et al. Antiviral activities of IFN-α and III interferons disrupt lung epithelial repair during recovery from viral infection. *J Virol* (2020) 94:01608–11. doi: 10.1128/jvi.01608-20

30. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol* (2020) 92:424–32.

31. Ziegler CGK, Allon SJ, Nyquist SK, Mbano I, Miao VN, Cao Y, et al. SARS-CoV-2 receptor ACE2 is an interferon–stimulated gene in human airway epithelial cells and is enriched in specific cell subsets across tissues. *Cell* (2020) 181:1016–35.e19.

32. Bailey CC, Zhong G, Huang I-C, Farzam M. IFITM-family proteins: the cell’s first line of antiviral defense. *Annu Rev Virol* (2014) 1:261–83. doi: 10.1146/annurev-virology-031413-085537

33. Békes M, Rut W, Kasperkiewicz P, Mulder MPC, Ovaa H, Drag M, et al. SARS hCoV papain-like protease is a unique Lys48 linkage-specific distributive deubiquitinating enzyme. *Biochem J* (2015) 468:215–26. doi: 10.1042/bj20141170

34. Mielech AM, Kiliński A, Baez-Santos YM, Meseck AD, Baker SC. MERS-CoV papain-like protease has deSGlytating and deubiquitinating activities. *Virology*. (2014) 450–451:64–70. doi: 10.1016/j.virol.2013.11.040

35. Trouillet-Assant S, Viel S, Gayd A, Pons S, Richard J-C, Perret M, et al. Type I IFN immunoprofiling in COVID-19 patients. *J Allergy Clin Immunol* (2020) 146:206–8.e2.

36. Lokugamage KG, Hage A, Schindewolf C, Rajbaum R, Menachery VD. SARS-CoV-2 is sensitive to type I interferon pretreatment. *bioRxiv*. (2020). [Preprint]. doi: 10.1101/2020.03.07.098264

37. Mantlo E, Bukreyeva N, uyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antiviral Res* (2020) 179:104811. doi: 10.1016/j.antiviral.2020.104811

38. Stockman IJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* (2006) 3:e343. doi: 10.1371/journal.pmed.0030343

39. Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. *Inflamm Res [Internet]*. (2020) 69:599–606. doi: 10.1007/s00011-020-01342-0

40. Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, et al. IFN-α is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. *EMBO Mol Med* (2016) 8:1099–112. doi: 10.15252/emmm.201606413

41. Galani IE, Triantafyllia V, Eleminiadou E-K, Koltsida O, Stavropoulos A, Manioudaki M, et al. Interferon-α mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. *Immunity* (2017) 46:875–90.6.e

42. Planet PJ, Parker D, Cohen TS, Smith H, Leon JD, Ryan C, et al. Lambda interferon restructures the nasal microenvironment and increases susceptibility to *Staphylococcus aureus* skin infection. *Schneewind O*, editor. *mBio*. (2016) 7:e01939–1915.

43. Rich HE, McCourt CC, Zheng WQ, McHugh KJ, Robinson KM, Wang J, et al. Interferon lambda inhibits bacterial uptake during influenza superinfection. *Infect Immun* (2019) 87:en114–9.

44. Blanco-Melo D, Nilsson-Payton BE, Liu W-C, Uhl S, Hoagland D, Moller R, et al. Interferon-related host response to SARS-CoV-2 drives development of COVID-19. *Cell* (2020) 181:1036–45.e9.

45. Stanifer ML, Kee C, Cortese M, Zuan CM, Triana S, Mukenhirn M, et al. Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells. *Cell Rep* [Internet]. (2020) 32:107863. doi: 10.1016/j.celrep.2020.107863

46. Major J, Crotta S, Llorian M, McCabe TM, Gad HH, Priestnall SL, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. *Science*. (2020) 369:712. doi: 10.1126/science.abc2061

47. Broggi A, Ghosh S, Sposito B, Spredaio R, Balzarini F, Lo Cascio A, et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. *Science*. (2020) 369:706. doi: 10.1126/science.abb3545

48. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. *Virology* (2006) 344:119–30. doi: 10.1016/j.virol.2005.08.0924

49. Rodríguez JJ, Parisien J-P, Horvath CM. Nipah virus protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. *J Virol* (2002) 76:11476–83. doi: 10.1128/jvi.76.22.11476-11483.2002
50. Shoikh S, Mahmoudvand S, Taherkhani R, Farshadpour F. Modulation of the immune response by Middle East respiratory syndrome coronavirus. J Cell Physiol. (2019) 234:2143–51. doi: 10.1002/jcp.27155

51. Zhao X, Nicholls JM, Chen Y-G. Severe Acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with smad3 and modulates transforming growth factor-β signaling. J Biol Chem. (2008) 283:3272–80. doi: 10.1074/jbc.m70033200

52. Knoops K, Kikkert M, Worm SHE, Zevenhoven-Dobbe JC, van der Meer Y, Koster AJ, et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. (2008) 6:e226–226. doi: 10.1371/journal.pbio.0060226

53. Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, Onderwater JJM, van der Meulen J, Koerten HK, et al. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. (2006) 80:5927–40. doi: 10.1128/jvi.02501-05

54. Li S-W, Wang C-Y, Jou V-J, Huang S-H, Hsiao L-H, Wan L, et al. SARS coronavirus papain-like protease inhibits the TR7 signaling pathway through removing Lys63-linked polyubiquitination of TRAF3 and TRAF6. Int J Mol Sci. (2016) 17:678. doi: 10.3390/ijms17050678

55. Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heit ME, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. (2015) e02638–615.

56. Fan Z, Zhou Y, Tan X, Zhou Z, Yuan J, Qiang B, et al. SARS-CoV nucleocapsid protein binds to hUbc9, a ubiquitin conjugating enzyme of the sumoylation system. J Med Virol. (2006) 78:1365–73. doi: 10.1002/jmv.20707

57. Faure E, Poissy J, Goiffard A, Fournier C, Kipnis E, Titeca M, et al. Distinct immune response in two MERS-CoV-Infected patients: can we go from bench to bedside? PLoS One. (2014) 9:e88716. doi: 10.1371/journal.pone.0088716

58. Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Snijder EJ, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus 2 infection. J Virol. (2013) 87:12489–95. doi: 10.1128/jvi.01845-13

59. Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T, et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol. (2013) 87:12489–95. doi: 10.1128/jvi.01845-13

60. Yang Y, Ye F, Zhu N, Wang W, Deng Y, Zhao Z, et al. Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets. Sci Rep. (2015) 5:17554.

61. Snijder EJ, van der Meer Y, Snijder EJ, Frieman MB. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J Gen Virol. (2014) 95(Pt 4):874–82. doi: 10.1099/vir.0.062059-0

62. Matthews KL, Coleman CM, van der Meer Y, Snijder EJ, Frieman MB. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J Gen Virol. (2014) 95(Pt 4):874–82. doi: 10.1099/vir.0.062059-0

63. Yang Y, Zhang L, Geng H, Deng Y, Huang B, Guo Y, et al. The structural and accessory proteins n, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell. (2013) 4:951–61. doi: 10.1007/s13238-013-0396-9

64. Conolly Y, Kimura I, Ujiu K, Fukushima M, Irie T, Koyanagi Y, et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant. BioRxiv. (2020). [Preprint]. doi: 10.1101/2020.05.11.088179

65. Hachim A, Kavian N, Cohen CA, Chin AW, Chu DK, Mok CKP, et al. Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients. medRxiv. (2020). [Preprint]. doi: 10.1101/2020.04.30.20085670

66. Yang C-K, Lam J-Y, Wong W-M, Mak L-F, Wang X, Chu H, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. (2020) 9:1418–28. doi: 10.1002/emm2.12751.2020.178095

67. Zheng Y, Zhuang M-W, Han L, Zhang J, Nan M-L, Gao C, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. bioRxiv. (2020). [Preprint]. doi: 10.1101/2020.07.26.222026

68. Lindner HA, Fotouhi-Ardakani N, Lytvyn V, Lachance P, Sulea T, Ménard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol. (2005) 79:15199. doi: 10.1128/jvi.79.24.15199-15208.2005

69. Bailey-Ellin BA, Knaap RCM, Johnson GG, Dalebout TJ, Nishtar DB, van Kasteren PB, et al. Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J Biol Chem. (2014) 289:34667–82. doi: 10.1074/jbc.m114.609644

70. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. (2020) 130:2620–9. doi: 10.1172/jci137244

71. Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. (2020) 20:656–7. doi: 10.1016/s1473-3099(20)30232-2

72. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically Ill patients with coronavirus disease 2019. Clin Infect Dis [Internet]. (2020) 17:ciaa449. doi: 10.1093/cid/ciaa449

73. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. (2020) 46:846–8. doi: 10.1007/s00134-020-05991-x

74. Inai Y, Kuba K, Neely GG, Yaghoubi-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. (2008) 133:235–49.

75. Nyati KK, Masuda K, Zaman MM-U, Dubey PK, Millrine D, Chalise JP, et al. TLR4-induced NF-κB and MAPK signaling regulate the IL-6 mRNA stabilizing protein Arid5a. Nucleic Acids Res. (2017) 45:2687–703. doi: 10.1093/nar/gkw064

76. Zhang X, Wu K, Wang D, Yue X, Song D, Zhu Y, et al. Nucleoside phosphor of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-κB. Virology. (2007) 365:324–35. doi: 10.1016/j.virology.2007.04.009

77. Cheng G, Zhong J, Chuang J, Chisari FV. Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proc Natl Acad Sci USA. (2007) 104:9305–40. doi: 10.1073/pnas.0703285104
10. Narasaratu, T., Yang, E., Samy, R.P., Ng, H.H., Poh, W.P., Liew, A-A., et al. Excessive neutrophil and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonia. *Am J Pathol.* (2011) 179:199–210. doi: 10.1016/j.ajpath.2011.03.013

11. Gupta, A.K., Joshi, M.B., Philippova, M., Erne, P., Hasler, P., Hahn, S., et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. *S. Lett.* (2010) 584:3193–7. doi: 10.1016/j.febiol.2010.06.006

12. Clark, R., Ma, A.C., Taveren, S.A., McDonald, B., Goodarzi, Z., Kelly, M.M., et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in tic blood. *Nat Med.* (2007) 13:463–9. doi: 10.1038/nm1565

13. McDonald, B., Davis, R.P., Kim, S.J., Tse, M., Esmon, C.T., Kolaczkowska, E., et al. Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. *Blood.* (2017) 129:1357–67. doi: 10.1182/blood-2016-09-741298

14. Meher Akshaya, K., Spinosa, M., Davis, J.P., Pope, N., Laubach, V.E., Su, G., et al. Novel role of IL-1β (Interleukin-1β) in neutrophil extracellular trap formation and abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol.* (2018) 38:843–53. doi: 10.1161/atvbaha.117.308997

15. Sil, P., Wicklum, H., Sureel, C., Raba, B. Macrophage-derived IL-1β enhances monosodium urate crystal-triggered NET formation. *Inflamm. Res.* (2017) 66:227–37. doi: 10.1007/s00011-016-1008-0

16. Xiong, Y., Liu, Y., Cao, L., Wang, D., Guo, M., Jiang, A., et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. *Emerg Microbes Infect.* (2020) 9:761–70. doi: 10.1080/22221751.2020.174736

17. de Bont, C.M., Boelens WC, Pruin GJM. NETosis, complement, and coagulation: a triangular relationship. *Cell Mol Immunol.* (2019) 16:19–27. doi: 10.1016/j.cmi.2019.03.011

18. Gao, T., Hu, M., Zhang, X., Li, H., Zhu, I., Liu, H., et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. *medRxiv.* (2020). doi: 10.1101/2020.03.29.20041962

19. Linjio J-F, Leclerc M, Chochois C, Monsallier J-M, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. *J Thromb Haemost JTH.* (2020) 18:1473–6. doi: 10.1111/jth.14869

20. Liu, X., Li, Z., Liu, S., Sun, J., Chen, Z., Jiang, M., et al. Potential therapeutic effects of dipyradomole in the severely ill patients with COVID-19. *Acta Pharm Sin B.* (2020) 20:1205–15. doi: 10.1016/j.apsb.2020.04.008

21. Zhang, C., Wang, X., Li, S., Twelkmeyer T., Wang, W., Zhang, S., et al. NK2A is a NK cell exhaustion checkpoint for HCV persistence. *Nat Commun.* (2019) 10:1507.

22. Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol.* (2020) 17:533–5. doi: 10.1016/j.cmi.2020.02.0402-2

23. Wang, W., He, J., Lie, P., Huang, L., Wu, S., Yongsping, L., et al. The definition and risks of cytokine release syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: disease characteristics and retrospective analysis. *medRxiv.* (2020). doi: 10.1101/2020.02.26.20063026

24. Yu, L., Tong, Y., Shen, G., Fu, A., Lai, Y., Zhou, X., et al. Immunodepletion with hypoxia: a potential high risk subtype of coronavirus disease 2019. *medRxiv.* (2020). doi: 10.1101/2020.03.03.20030850

25. Sivori, S., Vacca, P., Del Zotto, G., Munari, E., Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. *Cell Mol Immunol.* (2019) 16:430–41. doi: 10.1016/j.cmi.2019.02.06-4

26. Wang, F., Nie, J., Wang, H., Zhao, Q., Xiong, Y., Deng, L., et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J Infect Dis.* (2020) 221:1762–9. doi: 10.1093/infdis/jiaa150

27. Xia, C-Q., Xu, L-L., Wang, Z., Qin, Z-Q., Tong, Z-H., Huang, K-W., et al. The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome. *Am J Clin Pathol.* (2004) 121:507–11. doi: 10.1309/wpkl7-y2ak-fncr-fce5

28. Cifaldi L, Pricipce G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for
the pathogenesis of macrophage activation syndrome. *Arthritis Rheumatal.* (2015) 67:3037–46. doi: 10.1002/art.39295

123. Ferlazzo G, Pack M, Thomas D, Paludan C, Schmidt D, Strowig T, et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. *Proc Natl Acad Sci USA.* (2004) 101:16606–11. doi: 10.1073/pnas.0407522101

124. tin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming. *Nat Immunol.* (2004) 5:1260–5. doi: 10.1038/ni1138

125. de Groen RA, Bolkjes A, Hou J, Liu B-S, McPhee F, Friiborg J, et al. IFN-λ-mediated IL-12 production in macrophages induces IFN-γ production in human NK cells. *Eur J Immunol.* (2015) 45:250–9. doi: 10.1002/eji.201444903

126. André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. *Cell.* (2018) 175:1731–43.e13

127. Chen Y, Feng Z, Diao B, Wang R, Wang G, Wang C, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly imitates human spleens and lymph nodes. *medRxiv.* (2020). [Preprint].

128. Lavin Y, Mortha A, Rahman A, Merad M. Regulation of macrophage development and function in peripheral tissues. *Nat Rev Immunol.* (2015) 15:731–44. doi: 10.1038/nri3920

129. Merad M, tin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol.* [Internet]. (2020) 20:02365. doi: 10.1038/s41591-020-0313-4

130. Chen Y, Feng Z, Diao B, Wang R, Wang G, Wang C, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly imitates human spleens and lymph nodes. *medRxiv.* (2020). [Preprint].

131. Ural BB, Yeung ST, Damani-Yokota P, Devlin JC, de Vries M, Vera-Jim JC. A single-cell atlas of the peripheral immune response to severe COVID-19 revealed by single-cell RNA sequencing. *Immunity.* (2020) 5:eaax8756. doi: 10.1126/sciimmunol.aax8756

132. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. *medRxiv.* (2020). [Preprint].

133. Zhou J, Chu H, Li C, Wong BH-Y, Cheng Z-S, Poon VK-M, et al. Antibody neutralization of middle east respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. *J Infect Dis.* (2013) 209:1331–42. doi: 10.1093/infdis/jit504

134. Gielo-Bourboulis EJ, Neta MG, Rovina N, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host Microbe.* (2020) 27:992–1000.e3

135. Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Eifeld AJ, Walters KB, et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. *Proc Natl Acad Sci USA.* (2018) 115:E1012.

136. Gordon DE, g GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature [Internet].* (2020) 583:1–13. doi: 10.1038/s41586-020-2286-9

137. Keskinen P, Ronni T, Matkainen S, Lehtonen A, kunan I. Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells. *Immunology.* (1997) 91:421–9. doi: 10.1111/j.1365-2567.1997.00258.x

138. Fang W-F, Chen Y-M, Lin C-Y, Huang H-L, Heng Y, Chang Y-T, et al. Histone deacetylase 2 (HDAC2) attenuates lipopolysaccharide (LPS)-induced inflammation by regulating PPAR-γ expression. *J Inflamm.* (2018) 15:3.

139. Kong X, Fang M, Li P, Fang F, Xu Y. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. *J Mol Cell Cardiol.* (2009) 46:292–9. doi: 10.1016/j.yjmcc.2008.10.023
162. Miller A, Reandelar MJ, Fasciglione K, Roumea V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. (2020). [Preprint]. doi: 10.1101/2020.03.24.20042937

163. Fidel PL, Noverr MC. Could an unrelated live attenuated vaccine serve as a preventive measure to dampen tis inflammation associated with COVID-19 infection? mBio. (2020) 11:e007–20.

164. Klinger D, Blass I, Rapporton N, Linial M. Significantly improved COVID-19 outcomes in countries with Higher BCG Vaccination coverage: a multivariable analysis. medRxiv. (2020). [Preprint]. doi: 10.20944/preprints202006.0073.v1

165. Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. (2020) 395:1545–6. doi: 10.1016/s0140-6736(20)31025-4

166. O’Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. (2020) 20:335–7. doi: 10.1038/s41577-020-0337-y

167. Keating ST, Groh L, van der Heijden CDCC, Rodriguez H, dos Santos JC, Fanucchi S, et al. The Set7 lysine methyltransferase regulates plasticity in oxidative phosphorylation necessary for trained immunity induced by β-glucan. Cell Rep. (2020) 31:107548. doi: 10.1016/j.celrep.2020.107548

168. Jesenak M, Majtan J, Rennerova Z, Kyselovic J, Bacin P, Hrubisko M. Immunomodulatory effect of pleuran (β-glucan from Pleurotus ostreatus) in children with recurrent respiratory tract infections. Int Immunopharmacol. (2013) 13:395–9. doi: 10.1016/j.intimp.2012.11.020

169. Vetvicka V, Vetvickova I. Glucan supplementation enhances the immune response against an influenza challenge in mice. Ann Transl Med. (2015) 3:22–22.

170. Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, et al. Orally administered particulate β-Glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res. (2010) 16:3153. doi: 10.1158/1078-0432.ccr-10-0820

171. Hassanzadeh-Kiabi N, Yañez A, Dang I, tins GA, Underhill DM, Goodridge HS. Autocrine type I IFN signaling in dendritic cells stimulated with fungal β-glucans or lipopolysaccharide promotes CD8 T cell activation. J Immunol. (2017) 198:375. doi: 10.4049/jimmunol.1601143

172. Chaung H-C, Huang T-C, Yu J-H, Wu M-L, Chung W-B. Immunomodulatory effects of β-glucans on porcine alveolar macrophages and bone row hematopoietic cell-derived dendritic cells. Vet Immunol Immunopathol. (2009) 131:147–57. doi: 10.1016/j.vetimm.2009.04.004

173. Chan AS, Qiu X, Jonas AB, Patchen ML, Bose N. Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype. J Immunother Cancer. (2014) 2:191.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Taefehshokr, Taefehshokr, Hemmat and Heit. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.